company background image
2257 logo

Sirnaomics SEHK:2257 Stock Report

Last Price

HK$2.80

Market Cap

HK$225.7m

7D

2.6%

1Y

-94.1%

Updated

21 Nov, 2024

Data

Company Financials +

2257 Stock Overview

An RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. More details

2257 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Sirnaomics Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sirnaomics
Historical stock prices
Current Share PriceHK$2.80
52 Week HighHK$48.95
52 Week LowHK$2.35
Beta-0.27
11 Month Change-10.26%
3 Month Change9.80%
1 Year Change-94.09%
33 Year Changen/a
5 Year Changen/a
Change since IPO-96.41%

Recent News & Updates

Recent updates

Shareholder Returns

2257HK BiotechsHK Market
7D2.6%1.5%0.4%
1Y-94.1%-11.2%12.0%

Return vs Industry: 2257 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.

Return vs Market: 2257 underperformed the Hong Kong Market which returned 12% over the past year.

Price Volatility

Is 2257's price volatile compared to industry and market?
2257 volatility
2257 Average Weekly Movement12.7%
Biotechs Industry Average Movement10.9%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.3%

Stable Share Price: 2257 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2257's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200790Hung Fai Poonwww.sirnaomics.com

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.

Sirnaomics Ltd. Fundamentals Summary

How do Sirnaomics's earnings and revenue compare to its market cap?
2257 fundamental statistics
Market capHK$225.72m
Earnings (TTM)-HK$636.61m
Revenue (TTM)HK$8.39m

29.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2257 income statement (TTM)
RevenueUS$1.08m
Cost of RevenueUS$0
Gross ProfitUS$1.08m
Other ExpensesUS$82.88m
Earnings-US$81.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.94
Gross Margin100.00%
Net Profit Margin-7,587.85%
Debt/Equity Ratio-2.4%

How did 2257 perform over the long term?

See historical performance and comparison